This acquisition substantially complements Catalent’s global softgel abilities, adding a portfolio of OTC and prescription pharmaceutical products provided towards the United States market. Accucaps’ two condition-of-the-art facilities in Ontario, Canada offer integrated development, manufacturing and packaging solutions.
This acquisition strengthens Catalent’s capability to offer customers full-service, turnkey solutions and complements Catalent’s OTC and prescription softgel development and manufacturing expertise, along with its overall softgel production capacity.
Read full pr release here.
This acquisition occurs the heels of Catalent’s recent purchase of Pharmatek Laboratories, adding extensive early phase development and spray dry abilities to supply a fully comprehensive portfolio of drug development and bioavailability enhancement solutions. Find out more here.
Catalent RP Scherer Softgel is really a world leader in innovative dental and topical softgel technologies for that pharmaceutical, consumer health, and cosmetic markets. Accucaps’ two facilities in Windsor and Strathroy, Ontario, will be included to Catalent’s global network of 11 Softgel Technologies facilities. These facilities house significant blistering, bottling along with other packaging abilities, in addition to high-potency prescription softgel development and manufacturing that’s complementary to Catalent’s knowledge of innovative dental and topical softgel technologies.